Bioexcelife
Performance evaluation is one of the most important requirements for IVD manufacturers under the In Vitro Diagnostic Medical Devices Regulation (IVDR).
Under IVDR, manufacturers must show that their IVD is not only technically functional, but also clinically meaningful for its intended purpose. This means the device must deliver reliable results, support the right clinical decision, and remain safe and effective throughout its lifecycle.
In simple terms, performance evaluation answers one key question:
Can your IVD test do what it claims to do accurately, reliably, and in the right clinical context?
Why Performance Evaluation Matters Under IVDR
The IVDR has raised the expectations for clinical evidence. Manufacturers can no longer rely only on historical data or basic technical performance.
They must now present a clear and structured evidence package that supports the device’s intended purpose, risk class, target population, and clinical use.
According to MDCG 2022-2, performance evaluation for IVDs is a continuous process. It includes collecting, assessing, and updating clinical evidence throughout the lifecycle of the device.
This makes performance evaluation more than a submission requirement. It becomes a core part of product compliance and post-market confidence.
The Three Pillars of Performance Evaluation
A strong performance evaluation is built on three key pillars: scientific validity, analytical performance, and clinical performance.
Scientific validity explains the relationship between the analyte and the clinical condition. For example, it shows why a specific biomarker is relevant for detecting or monitoring a disease.
Analytical performance shows how well the test measures what it is designed to measure. This may include accuracy, precision, sensitivity, specificity, repeatability, reproducibility, and detection limits.
Clinical performance shows how well the test result relates to the clinical condition or intended clinical use in the target population.
Together, these three pillars form the foundation of the Performance Evaluation Report (PER).
PER Is Not Just a Report
Many manufacturers think performance evaluation ends once the PER is prepared.
That is not correct.
Under IVDR, the PER must stay updated. It should reflect new clinical evidence, post-market data, complaints, trends, and results from Post-Market Performance Follow-up (PMPF).
This is why performance evaluation must connect closely with risk management, PMS, and PMPF. If new data shows a performance concern, the PER should not remain unchanged. The manufacturer must review the evidence and update the conclusions where needed.
The European Commission’s MDCG guidance list also includes guidance on performance studies and performance evaluation for IVDs, showing how important this topic is for IVDR compliance.
Common Mistakes Manufacturers Make
One common mistake is preparing the PER like a traditional technical summary. A strong PER must do more than describe test performance. It must explain why the evidence is enough.
Another mistake is weak linkage between intended purpose and evidence. If the intended purpose is broad, but the performance data is narrow, Notified Bodies may raise questions.
Some manufacturers also underestimate PMPF. They prepare a plan, but the activities are too generic or not clearly linked to remaining performance uncertainties.
These gaps can delay certification and create avoidable review questions.
What Notified Bodies Expect
Notified Bodies want to see a clear performance story.
They expect the manufacturer to define the intended purpose properly, identify performance claims, collect suitable evidence, and explain how that evidence supports safety and performance.
They also expect traceability. The intended purpose, claims, analytical studies, clinical performance data, risk management, PMS, and PMPF should all connect logically.
If these elements do not align, the submission becomes weak.
Why This Is Critical for IVD Manufacturers
IVDR has changed the way IVDs are reviewed in Europe. Many IVDs now require stronger evidence and Notified Body involvement compared with the previous IVDD system.
This means manufacturers must plan performance evaluation early. Waiting until submission stage can lead to evidence gaps, rushed PMPF planning, and weak justification.
A strong performance evaluation strategy helps reduce these risks and supports smoother market access.
Performance evaluation under IVDR is not just about proving that a test works.
It is about proving that the test is scientifically valid, analytically reliable, and clinically meaningful.
A well-prepared PER gives confidence to regulators, Notified Bodies, healthcare professionals, and patients. More importantly, it shows that the manufacturer understands the device, its claims, its risks, and its role in clinical decision-making.
How Bioexcel Can Help
At Bioexcel, we support IVD manufacturers with performance evaluation planning, PER preparation, PMPF strategy, clinical evidence gap assessment, and IVDR technical documentation alignment.
We help ensure your performance evaluation is not just complete, but clear, defensible, and review-ready.
Need support with Performance Evaluation under IVDR? Partner with Bioexcel for a stronger path to compliance and market success.
